Introduction
Currently, some studies have described an association between the radiation-induced lymphopenia with poor oncologic outcome, indicating that radiotherapy using large volumes and multiple daily fractions can lead to immunosuppression [8, 9]. On the other side, some studies have shown potential therapeutic benefits by eventual ablation of regulatory (“suppressor”) T cells with limited (single-dose) systemic therapies [10‐12] given “at the right time” in order to selectively ablate those suppressor T cells while sparing the effector T cells. Thus, suggesting that the accurate timing of limited therapy may play a major role in treatment efficacy. Following the recent reports of the anti-tumor immune response oscillating over several days [13‐16], we hypothesized the following: by monitoring before the treatment immune-specific biomarkers as the surrogates of homeostatically fluctuating immune response, which is cyclically suppressed and incited (“switched off and on”), it would be possible to determine a periodicity of immune response and, based on that, to synchronize SBRT-PATHY with its most excitable phase, in order to overcome tumor tolerance locally and systemically.In order to improve the therapeutic-ratio by exploiting BE/AE an unconventional partial tumor irradiation targeting the hypoxic segment was developed in 2016 in our institute [2]. Our preclinical findings indicated that the hypoxic in respect to normoxic tumor cells, if selectively irradiated as inductor of BE/AE, show higher potential for the generation of BE/AE [3]. The subsequent translation of these findings to a clinic led to the introduction of a novel SBRT-based PArtial Tumor irradiation targeting HYpoxic clonogenic cells (SBRT-PATHY) showing promising BE/AE-response rates [2, 4]. Recently, the Italian group confirmed efficacy of SBRT-PATHY in their initial experience [5]. Considering the immune-mediated nature of BE/AE and in order to further improve BE/AE response rate, SBRT-PATHY was upgraded in 2018 by the sparing of peritumoral immune microenvironment as a new OAR, defined by its own dose-constraints [4, 6]. Our concept implied that for successful therapeutic immune modulation, the entire tumor volume may not need to be irradiated but only a part of the tumor. This should initiate antigen shedding, increase effector T cell activation and lead to favorable alterations in radiation-spared peritumoral immune environment [7].
Materials and methods
Timing of SBRT-PATHY with respect to an underlying fluctuating anti-tumor immune response
Patients
FEATURES: | Number of patients (total 8): |
---|---|
GENDER: | |
Male | 5 |
Female | 3 |
AGE (years): | |
Mean | 68.4 |
Range | 57–80 |
ECOG PERFORMANCE STATUS: | |
0–1 | 6 |
2–3 | 2 |
PRIMARY TUMOR SITE: | |
Skin | 1 |
Breast | 1 |
Lung | 6 |
HISTOLOGY: | |
Adenocarcinoma (lung) | 3 |
Adenocarcinoma (breast) | 1 |
Squamous (lung) | 3 |
Malignant melanoma | 1 |
TREATED BULKY TUMOR SITE: | |
Lung primary | 6 |
Neck lymph node metastasis (skin melanoma) | 1 |
Bone metastasis (breast) | 1 |
BULKY TUMOR PATIENTS WITH DISTANT OLIGOMETASTASES: | 3 |
Lung primary(1), malignant melanoma (1), Breast(1), | |
BULKY TUMOR PATIENTS WITH LYMPH NODE METASTASES ONLY: | 5 |
Lung primary(5) | |
UNRESCTABLE BULKY TUMOR DIAMETER: mean/range (cm) | 10.1/6.6–13.8 |
UNRESCTABLE BULKY TUMOR VOLUME: mean/range (cm3) | 375.4/121.5–901.8 |
TARGETED BULKY TUMOR HYPOXIC SEGMENT: mean/range (cm3) | 124.7/41.9–442.9 |
SYSTEMIC THERAPY (exclusively before SBRT-PATHY) | |
Chemotherapy | 1 |
Immunotherapy | 1 |
SYMPTOMS related to bulky disease: | |
Pain | 6 |
Dyspnea | 7 |
Cough | 5 |
Haemoptysis | 2 |
PATIENTS TREATED AT “MOST FAVOURABLE” DAY: | 4 |
Lung primary: squamous(1) and adenocarcinoma(1) | 2 |
Neck lymph node metastasis of malignant melanoma of the skin | 1 |
Bone metastasis of breast adenocarcinoma | 1 |
PATIENTS TREATED AT “LEAST FAVOURABLE” DAY: | 4 |
Lung primary: squamous(2) and adenocarcinoma(2) | 4 |